David Fellows
Chief Executive Officer chez APPLIED GENETIC TECHNOLOGIES CORPORATION
Fortune : - $ au 31/03/2024
Profil
David A.
Fellows is currently the Chief Executive Officer & Secretary at Beacon Therapeutics (USA), Inc. He is also the Chairman at Oxular Ltd.
and Terns Pharmaceuticals, Inc. Additionally, he serves as the Director at Glaucoma Foundation and Gyroscope Therapeutics Ltd.
Furthermore, he holds positions as a Director at Jaguar Therapeutics, Arctos Medical, and Jaguar Gene Therapy LLC.
In his former roles, Mr. Fellows served as the Chief Executive Officer & Director at Nightstar Therapeutics Ltd.
from 2017 to 2019.
He was also the Managing Director at Allergan Ltd.
and a Director at NightstaRx Ltd.
and Axovia Therapeutics, Inc. Moreover, he held the position of Non-Executive Director at Gyroscope Therapeutics Holdings Plc from 2020 to 2022.
Additionally, he worked as a Vice President at Allergan, Inc. and Johnson & Johnson Vision Care, Inc. from 2005 to 2014.
Mr. Fellows completed his undergraduate degree at Butler University.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
12/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de David Fellows
Sociétés | Poste | Début |
---|---|---|
TERNS PHARMACEUTICALS, INC. | Chairman | 01/02/2021 |
APPLIED GENETIC TECHNOLOGIES CORPORATION | Chief Executive Officer | 01/11/2022 |
Oxular Ltd.
Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Chairman | 10/01/2017 |
Glaucoma Foundation | Director/Board Member | 01/05/2006 |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Director/Board Member | 01/12/2020 |
Jaguar Therapeutics | Director/Board Member | - |
Arctos Medical | Director/Board Member | - |
Jaguar Gene Therapy LLC
Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | Director/Board Member | 01/08/2020 |
Anciens postes connus de David Fellows
Sociétés | Poste | Fin |
---|---|---|
GYROSCOPE THERAPEUTICS HOLDINGS PLC | Director/Board Member | 17/02/2022 |
░░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░ ░░░░░░░ ░░░░░░ ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de David Fellows
Butler University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
TERNS PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 14 |
---|---|
Allergan, Inc.
Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
Beacon Therapeutics (USA), Inc.
Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
Allergan Ltd.
Allergan Ltd. Pharmaceuticals: MajorHealth Technology Allergan Ltd. provides eye care and specialty pharmaceutical products. It develops pharmaceutical products used for treatment of eye and skin care medications and neurological disorders. The firm develops products for glaucoma, dry eye, blepharospasm, cervical, dystonia, hemi-facial spasm, post-stroke spasticity and cerebral palsy. The company was founded in 1977 and is headquartered in Marlow, the United Kingdom. | Health Technology |
Johnson & Johnson Vision Care, Inc.
Johnson & Johnson Vision Care, Inc. Electronic ComponentsElectronic Technology Johnson & Johnson Vision Care, Inc. manufactures and markets vision care products. The company was founded on March 07, 1962 and is headquartered in Jacksonville, FL. | Electronic Technology |
Glaucoma Foundation | |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Oxular Ltd.
Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Nightstar Therapeutics Ltd.
Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Axovia Therapeutics, Inc.
Axovia Therapeutics, Inc. BiotechnologyHealth Technology Part of Axovia Therapeutics Ltd., Axovia Therapeutics, Inc. is dedicated to developing disease-transformative therapies that target key aspects of ciliopathies. The American company is working to advance gene therapy programs that have already shown early promise in treating some of the most severe aspects of bbs, such as early onset blindness and neurometabolic disease. The private company was founded by Philip Beales, Victor Hernandez, and Philip Beales has been the CEO since incorporation. Axovia Therapeutics was acquired by Alsa Management Services Ltd on September 19, 2023. | Health Technology |
Jaguar Gene Therapy LLC
Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | Health Services |
Gyroscope Therapeutics Holdings Plc
Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Jaguar Therapeutics | |
Arctos Medical |